Renal Mechanism of SGLT2 Inhibition

NCT05507892 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes
Diabetic Kidney Disease

Interventions

DRUG: canagliflozin
DRUG: Aminohippurate Sodium Inj 20%

Sponsor

University of Colorado, Denver

Collaborators

[object Object]